On the evening of April 29th, Notai Bio (688076) released its 2025 annual report and 2026 Q1 report simultaneously. Despite a complex external environment, the company achieved operating revenue of 1.943 billion yuan in 2025, a year-on-year increase of 19.57%; net profit attributable to shareholders was 332 million yuan, and net profit excluding non-recurring items was 366 million yuan. In Q1 2026, the company achieved operating revenue of 553 million yuan, a slight year-on-year decrease of 2.23%, and net profit attributable to shareholders of 129 million yuan.
